


Masonic Cancer Center Research Symposium



Speakers



Douglas Yee, MD

Dr. Yee is a medical oncologist with a specialty in breast cancer. His lab has been interested in the regulation of cancer cells by the insulin-like growth factors (IGFs) and insulin. He also maintain an active clinical practice in the medical management of breast cancer. As part of his clinical care, he serves as the site principal investigator on several clinical trials that employ experimental therapies targeted against IGF receptor and the PI3K pathway. He is the chair in of the Agent Selection Committee of I-SPY2 and serves on the Executive Committee of this trial designed to validate investigational therapies in the neoadjuvant treatment of breast cancer. He has been the director of the Masonic Cancer Center since 2007.



Electra Paskett, PhD

Dr. Paskett became the Marion N. Rowley Professor of Cancer Research at The Ohio State University in 2002. She is the Director of the Division of Cancer Prevention and Control in the College of Medicine, a professor in the Division of Epidemiology in the College of Public Health, and the Associate Director for Population Science^{3s} and Program Leader of the Cancer Control Program in the Comprehensive Cancer Center of The Ohio State University (OSU). She is also Director of the Center for Cancer Health Equity at the James Cancer Hospital. Dr. Paskett's research program is nationally recognized for studying cancer health disparities utilizing a "team science approach."



Jen Poynter, PhD

Jen Poynter, PhD, is a Professor in the Division of Epidemiology and Clinical Research in the Department of Pediatrics. Dr. Poynter is a molecular epidemiologist who leads a research team focused on pediatric and adolescent germ cell tumors (GCT) and myeloid malignancy. The major goals of her GCT research are to understand genetic susceptibility, epigenetic alterations and late effects of treatment, including ototoxicity and neuropathy. She is also working on studies to understand how lifestyle and genetic factors influence risk of developing pediatric and adult myelodysplastic syndromes (MDS).

Masonic Cancer Center Research Symposium



Speakers



Dorothy Hatsukami, PhD

Dr. Hatsukami is the Forster Family Chair in Cancer Prevention at the Masonic Cancer Center of the University of Minnesota and a Professor of Psychiatry and Behavioral Sciences. She is also the Associate Director of Cancer Prevention and Control at the University of Minnesota Masonic Cancer Center, Director of the Tobacco Research Programs, and Deputy Director of the Global Institute for Research on Cancer Prevention. Her current work focuses on assessing the toxicity, appeal, and addictiveness of various tobacco products with the goal of reducing tobacco-caused harm and addiction.



David Odde, PhD

David Odde is a professor of biomedical engineering at the University of Minnesota who studies the mechanics of cell division and migration. Trained academically as chemical engineer, Odde joined the newly created Department of Biomedical Engineering at the University of Minnesota in 1999. In his research, Odde's group builds computer models of cellular and molecular self-assembly and force-generation-dissipation dynamics, and tests the models experimentally using digital microscopic imaging of cells ex vivo and in engineered microenvironments. Dr. Odde is an elected Fellow of the American Institute for Medical and Biological Engineering (AIMBE) and the Biomedical Engineering Society (BMES).



Branden Moriarity, PhD

Dr. Moriarity is currently an Associate Professor in the Department of Pediatrics, Division of Hematology/Oncology. He joined the Department of Pediatrics Faculty in 2014. Dr. Moriarity runs a basic/translational research laboratory working to develop novel cellular therapeutics for gene therapy and cancer immunotherapy with the goal of translating new therapeutics to the clinic. The Moriarity lab also performs preclinical drug testing for pediatric cancers in order to launch new clinical trials using antibody therapies rather than toxic chemotherapy.

Masonic Cancer Center Research Symposium



Speakers



Scott Dehm, PhD

Dr. Dehm is a member of the Division of Molecular Pathology and Denomics. His research laboratory focuses on the role of the androgen receptor (AR) and alterations in AR signaling in prostate cancer development and progression. Dr. Dehm's research team employs a variety of genomic engineering, molecular biology, and biochemistry tools to hone in on the regulatory behavior of the AR and the signals it uses to promote resistance.



Anna Prizment, PhD

A cancer epidemiologist, Dr. Prizment studies cancer prevention and survival of cancer patients, with her research focused on the role of inflammation and immune response, as measured by circulating and tissue biomarkers, genetic alterations and gut microbiome, in gastrointestinal cancers. A second focus is the role of aspirin and other anti-inflammatory agents in colorectal cancer.